Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

eculizumab

- PMLiVE

Morning brief: Sanofi’s shaky start, pharma begins talks with UK government and more

Sanofi falling behind in Amgen cholesterol battleFirst quarter results from Sanofi show the company has got off to shaky start in 2018, including signs that it its PCKS9 inhibitor cholesterol...

- PMLiVE

Alexion adds to pipeline rebuild with $855m Wilson buy

Also acquires the Swedish group’s lead product for Wilson’s disease

- PMLiVE

Alexion appoints new senior VP for EMEAC region

Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland

- PMLiVE

Alexion’s Soliris gets US approval for myasthenia gravis

New neurology indication could contribute $1.2bn to sales, says analysts

- PMLiVE

AAA’s orphan drug Lutathera wins EU green light

The first-in-class drug treats adults with GEP-NET

- PMLiVE

Germany will be first EU launch market for new Soliris indication

Alexion 'currently evaluating' additional European launches for its orphan drug

- PMLiVE

European Commission approves Dompé’s orphan drug

Oxervate will treat patients with neurotrophic keratitis

- PMLiVE

NICE broadens access to Alexion’s rare disease drug Strensiq

New deal offers NHS England a discount for the drug

- PMLiVE

NICE blocks second Alexion rare disease drug in a week

Says high cost and “considerable uncertainties” over long-term benefits prohibit routine NHS use

Alexion Pharmaceutiacal names interim CEO and CFO

Former AZ CEO David Brennan and David Anderson join

- PMLiVE

NICE wants more data on Alexion’s orphan drug Kanuma

Calls for 'robust evidence' about the costly rare disease treatment's price and benefits

- PMLiVE

Alexion’s rare bone disorder therapy rejected by NICE

Draft guidance rules Strensiq does not have a compelling enough evidence base

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links